Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

NCT00630409 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00630409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
Lead sponsor
University of Pittsburgh
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
September 30, 2009
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma